Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.47 |
| ▸ | ERN1 | O75460 | 7/20 | 0.46 |
| ▸ | PRKDC | P78527 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31540801 | 1.00 | SRC (0.47) | SRCERN1PRKDCALDH1A1LMNA | |
| SCHEMBL29387108 | 0.82 | ALDH1A1 (0.50) | SRCERN1PRKDCALDH1A1LMNA | |
| SCHEMBL136361 | 0.82 | ALDH1A1 (0.50) | SRCERN1PRKDCALDH1A1LMNA | |
| SCHEMBL7863855 | 0.79 | HTT (0.44) | ERN1PRKDCALDH1A1LMNAMAPT | |
| SCHEMBL29746806 | 0.79 | HTT (0.44) | ERN1PRKDCALDH1A1LMNAMAPT | |
| SCHEMBL2888296 | 0.78 | ERN1 (0.52) | SRCERN1ALDH1A1LMNAHPGD | |
| SCHEMBL2691345 | 0.78 | CYP2A6 (0.48) | SRCERN1PRKDCALDH1A1LMNA | |
| SCHEMBL16308860 | 0.77 | TP53 (0.40) | SRCALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL2602660 | 0.77 | TP53 (0.40) | SRCALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL16961277 | 0.77 | ALOX5 (0.40) | SRCERN1ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112679541-B | Preparation method and application of metal organic ternary cyclic compound | 大连理工大学 | 2022-03-18 | — | — | CN | claimed |
| CN-112679541-A | Preparation method and application of metal organic ternary cyclic compound | 大连理工大学 | 2021-04-20 | — | — | CN | claimed |
| US-20100234396-A1 | Tetrhydropyridoindole Derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-16 | — | — | US | claimed |
| CN-1930162-B | Tetrahydropyridoindole derivatives | ACTELION PHARMACEUTICALS LTD | 2010-06-16 | — | — | CN | claimed |
| EP-1725553-B1 | TETRAHYDROPYRIDOINDOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-05-07 | — | — | EP | claimed |
| US-20070191416-A1 | Tetrahydropyridoindole derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2007-08-16 | — | — | US | claimed |
| CN-1930162-A | Tetrahydropyridoindole derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2007-03-14 | — | — | CN | claimed |
| EP-1725553-A1 | TETRAHYDROPYRIDOINDOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-11-29 | — | — | EP | claimed |
| WO-2005095397-A1 | TETRAHYDROPYRIDOINDOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2005-10-13 | — | — | WO | claimed |
| EP-3573972-B1 | RORGAMMA MODULATORS AND USES THEREOF | GENFIT (FR) | 2026-01-14 | — | — | EP | disclosed |
| US-12398089-B2 | Method for preparing organic carboxylic ester by using combined catalyst of aryl bidentate phosphine ligand | NANJING CHENGZHI CLEAN ENERGY CO. LTD. (CN) | 2025-08-26 | — | — | US | disclosed |
| CN-118146234-A | 6,5,7,6-Tetracyclic derivatives, preparation method and application thereof | 浙江我武翼方药业有限公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2024114672-A1 | 6,5,7,6-TETRACYCLIC DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江我武翼方药业有限公司 | 2024-06-06 | — | — | WO | disclosed |
| WO-2023208151-A1 | USP INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION | 北京华森英诺生物科技有限公司 | 2023-11-02 | — | — | WO | disclosed |
| EP-1725553-B1 | TETRAHYDROPYRIDOINDOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-05-07 | — | — | EP | disclosed |
| US-20080051416-A1 | Novel Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-28 | — | — | US | disclosed |
| US-20070191416-A1 | Tetrahydropyridoindole derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2007-08-16 | — | — | US | disclosed |
| CN-1930162-A | Tetrahydropyridoindole derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2007-03-14 | — | — | CN | disclosed |
| EP-1725553-A1 | TETRAHYDROPYRIDOINDOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005095397-A1 | TETRAHYDROPYRIDOINDOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234396-A1 | Tetrhydropyridoindole Derivatives | TPH2, TPH1, HTR5A | SRC 2972/4885ERN1 4788/4885PRKDC 1910/4885 |
| US-12398089-B2 | Method for preparing organic carboxylic ester by using combined catalyst of aryl bidentate phosphine ligand | POF1B, ADH1C, OSBP | SRC 2243/4885ERN1 1333/4885PRKDC 1394/4885 |
| US-20080051416-A1 | Novel Compounds | MAPK1, MAPKAPK2, MAPK6 | SRC 498/4885ERN1 814/4885PRKDC 436/4885 |
| US-20070191416-A1 | Tetrahydropyridoindole derivatives | TPH2, TPH1, HTR2C | SRC 2053/4885ERN1 4771/4885PRKDC 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.